# A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)

> **NCT06305234** · — · RECRUITING · sponsor: **BioMarin Pharmaceutical** · enrollment: 200 (estimated)

## Conditions studied

- Phenylketonuria (PKU)

## Interventions

- **DRUG:** Pegvaliase

## Key facts

- **NCT ID:** NCT06305234
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-20
- **Primary completion:** 2033-11-18
- **Final completion:** 2033-11-18
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305234, "A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06305234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*